BRPI0108553B8 - processo para a purificação de hormônio luteinizante (lh) recombinante humano - Google Patents

processo para a purificação de hormônio luteinizante (lh) recombinante humano

Info

Publication number
BRPI0108553B8
BRPI0108553B8 BRPI0108553A BR0108553A BRPI0108553B8 BR PI0108553 B8 BRPI0108553 B8 BR PI0108553B8 BR PI0108553 A BRPI0108553 A BR PI0108553A BR 0108553 A BR0108553 A BR 0108553A BR PI0108553 B8 BRPI0108553 B8 BR PI0108553B8
Authority
BR
Brazil
Prior art keywords
purification
luteinizing hormone
recombinant human
human luteinizing
reversed
Prior art date
Application number
BRPI0108553A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0108553A (pt
BRPI0108553B1 (pt
Inventor
Paradisi Gianfranco
Scaglia Laura
Rossi Mara
Original Assignee
Applied Res Systems Ars Holding N V
Laboratoires Serono S A
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Res Systems Ars Holding N V, Laboratoires Serono S A, Merck Serono Sa filed Critical Applied Res Systems Ars Holding N V
Publication of BR0108553A publication Critical patent/BR0108553A/pt
Publication of BRPI0108553B1 publication Critical patent/BRPI0108553B1/pt
Publication of BRPI0108553B8 publication Critical patent/BRPI0108553B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0108553A 2000-02-22 2001-01-22 processo para a purificação de hormônio luteinizante (lh) recombinante humano BRPI0108553B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00103692 2000-02-22
PCT/EP2001/000666 WO2001062774A2 (en) 2000-02-22 2001-01-22 Purified lh

Publications (3)

Publication Number Publication Date
BR0108553A BR0108553A (pt) 2003-12-23
BRPI0108553B1 BRPI0108553B1 (pt) 2016-06-14
BRPI0108553B8 true BRPI0108553B8 (pt) 2021-05-25

Family

ID=8167926

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0108553A BRPI0108553B8 (pt) 2000-02-22 2001-01-22 processo para a purificação de hormônio luteinizante (lh) recombinante humano
BR122012018280A BR122012018280B8 (pt) 2000-02-22 2001-01-22 composição farmacêutica compreendendo hormônio luteinizante humano e sacarose

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122012018280A BR122012018280B8 (pt) 2000-02-22 2001-01-22 composição farmacêutica compreendendo hormônio luteinizante humano e sacarose

Country Status (30)

Country Link
US (2) US7053054B2 (https=)
EP (2) EP1777231A3 (https=)
JP (1) JP4959898B2 (https=)
KR (1) KR100808149B1 (https=)
CN (1) CN100480258C (https=)
AT (1) ATE356138T1 (https=)
AU (1) AU780377B2 (https=)
BG (1) BG65761B1 (https=)
BR (2) BRPI0108553B8 (https=)
CA (1) CA2399100C (https=)
CY (1) CY1108056T1 (https=)
CZ (1) CZ303274B6 (https=)
DE (1) DE60127100T2 (https=)
DK (1) DK1261622T3 (https=)
EA (1) EA004385B1 (https=)
EE (1) EE04932B1 (https=)
ES (1) ES2278722T3 (https=)
HR (1) HRP20020651B1 (https=)
HU (1) HU227007B1 (https=)
IL (2) IL151309A0 (https=)
MX (1) MXPA02007867A (https=)
NO (1) NO328693B1 (https=)
PL (1) PL207728B1 (https=)
PT (1) PT1261622E (https=)
RS (1) RS50416B (https=)
SI (1) SI1261622T1 (https=)
SK (1) SK287041B6 (https=)
UA (2) UA92145C2 (https=)
WO (1) WO2001062774A2 (https=)
ZA (1) ZA200206108B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE356138T1 (de) * 2000-02-22 2007-03-15 Applied Research Systems Gereinigtes recombinantes hlh mit spezifischer bioaktivität und verfahren zu dessen reinigung
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE602004030546D1 (de) 2003-03-04 2011-01-27 Aspenbio Pharma Inc LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers.
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
CA2544333A1 (en) * 2003-12-22 2005-07-14 Ares Trading S.A. Method for purifying fsh
JP2007513192A (ja) * 2004-10-04 2007-05-24 ノベタイド，リミティド ペプチド用の対イオン交換法
AU2005303818B2 (en) * 2004-11-09 2011-06-23 Ares Trading S.A. Method for purifying FSH
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
EP1960419B1 (en) * 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
CA2701221A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
EP2203474A1 (en) * 2007-10-22 2010-07-07 Merck Serono S.A. Method for purifying fc-fusion proteins
CN101928342B (zh) * 2009-06-18 2013-05-08 上海天伟生物制药有限公司 一种高纯度绝经期促性腺素及其制备方法和用途
CN106999546A (zh) * 2014-05-01 2017-08-01 弗吉尼亚技术知识资产公司 角蛋白纳米材料及其制备方法
CN104569441B (zh) * 2015-01-19 2016-02-03 成都大熊猫繁育研究基地 大熊猫尿液促黄体素的酶联检测方法及其应用
CA3140267A1 (en) 2019-05-16 2020-11-19 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non-human mammals using recombinant luteinizing hormone

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein
ES2098261T3 (es) * 1989-02-21 1997-05-01 Univ Washington Formas modificadas de hormonas reproductoras.
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
SI0996629T1 (sl) * 1997-06-25 2006-12-31 Applied Research Systems Analogi glikoproteinskega hormona povezanega z disulfidi, priprava in uporaba
ATE356138T1 (de) * 2000-02-22 2007-03-15 Applied Research Systems Gereinigtes recombinantes hlh mit spezifischer bioaktivität und verfahren zu dessen reinigung

Also Published As

Publication number Publication date
EA200200893A1 (ru) 2003-02-27
HU227007B1 (en) 2010-04-28
EP1261622B1 (en) 2007-03-07
NO20023963D0 (no) 2002-08-20
HK1052014A1 (zh) 2003-08-29
SK12052002A3 (sk) 2002-12-03
ZA200206108B (en) 2003-07-31
US20060079460A1 (en) 2006-04-13
JP2003532636A (ja) 2003-11-05
HRP20020651B1 (en) 2011-01-31
EP1777231A2 (en) 2007-04-25
SI1261622T1 (sl) 2007-06-30
CA2399100C (en) 2011-11-08
EP1777231A3 (en) 2007-11-07
UA92145C2 (en) 2010-10-11
DE60127100D1 (de) 2007-04-19
EE04932B1 (et) 2007-12-17
BR0108553A (pt) 2003-12-23
BRPI0108553B1 (pt) 2016-06-14
ES2278722T3 (es) 2007-08-16
ATE356138T1 (de) 2007-03-15
HUP0301814A2 (hu) 2003-08-28
KR100808149B1 (ko) 2008-02-29
BG107001A (bg) 2003-04-30
BG65761B1 (bg) 2009-10-30
AU3543601A (en) 2001-09-03
DE60127100T2 (de) 2007-06-28
DK1261622T3 (da) 2007-05-29
YU60302A (sh) 2005-09-19
CZ20022856A3 (cs) 2003-01-15
CN100480258C (zh) 2009-04-22
NO20023963L (no) 2002-08-20
NO328693B1 (no) 2010-04-26
CA2399100A1 (en) 2001-08-30
BR122012018280B1 (pt) 2018-01-09
EA004385B1 (ru) 2004-04-29
CZ303274B6 (cs) 2012-07-11
WO2001062774A2 (en) 2001-08-30
PL207728B1 (pl) 2011-01-31
EE200200464A (et) 2003-12-15
JP4959898B2 (ja) 2012-06-27
UA78676C2 (en) 2007-04-25
IL151309A (en) 2010-11-30
HUP0301814A3 (en) 2004-10-28
RS50416B (sr) 2009-12-31
IL151309A0 (en) 2003-04-10
PL362891A1 (en) 2004-11-02
SK287041B6 (sk) 2009-10-07
PT1261622E (pt) 2007-04-30
BR122012018280B8 (pt) 2021-05-25
CY1108056T1 (el) 2013-09-04
CN1404486A (zh) 2003-03-19
US7053054B2 (en) 2006-05-30
AU780377B2 (en) 2005-03-17
KR20030001358A (ko) 2003-01-06
US20030186893A1 (en) 2003-10-02
MXPA02007867A (es) 2003-02-10
HRP20020651A2 (en) 2004-12-31
EP1261622A2 (en) 2002-12-04
WO2001062774A3 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
BRPI0108553B8 (pt) processo para a purificação de hormônio luteinizante (lh) recombinante humano
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
WO2003025121A3 (en) Igf-binding protein-derived peptide or small molecule
PL354769A1 (en) Method of purification of pharmacologically acyive proteins using positive ion-exchange chromatography
BRPI0108556B8 (pt) processo para purificação de gonadotropina coriônica humana recombinante (hcg).
EP1192963A4 (en) ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS
WO2002060923A3 (en) B-superfamily conotoxins
ES2161790T3 (es) Procedimiento de separacion y de purificacion de proteinas dependientes de la vitamina k.
HU9600455D0 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating hiv infections
BR0010677B1 (pt) processo de purificaÇço de gonadotropinas urinÁrias humanas a partir de gonadotropinas brutas.
ATE309811T1 (de) Analgetikum aus schlangengift
WO2002004487A3 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
DE60112424D1 (de) Protonen-abhängiges na+kanal hemmendes polypeptid
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/06/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/01/2021